Runt (Runt domain)-related transcription factor 1 (RUNX1) is a transcription factor belonging to the core-binding factor (CBF) family. It is considered to be a master regulator of hematopoiesis and has been regarded as a tumor suppressor because it is essential for definitive hematopoiesis in vertebrates. It is one of the most frequent target genes of chromosomal translocation in leukemia, and germ line mutation of RUNX1 causes familial platelet disorder with associated myeloid malignancies. Somatic cell mutations and chromosomal abnormalities, including those of RUNX1, are observed in myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia at a high frequency.
| INTRODUCTION
Runt (Runt domain)-related transcription factor 1 (RUNX1), also known as acute myeloid leukemia 1 protein, is an important transcription factor involved in hematopoietic stem cell differentiation. 1 It is one of the most frequent target genes of chromosomal translocation in leukemia, and germ line mutation of RUNX1 causes familial platelet disorder with associated myeloid malignancies. Somatic cell mutations and chromosomal abnormalities, including those of RUNX1, are observed in myelodysplastic syndrome, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelomonocytic leukemia at a high frequency. [2] [3] [4] [5] RUNX1 is one of the RUNX family proteins (RUNX1, RUNX2, RUNX3), and each forms a heterodimer with core-binding factor β (CBFβ:PEBP2B). 6, 7 RUNX regulates transcription of target genes by recognizing and binding to the core consensus sequence, 5′-TGTGGT-3′, and in rare cases, to 5′-TGCGGT-3′, through the RUNT domain. 6, 7 Core-binding factor β is non-DNA-binding subunit that enhances the transcription activity of RUNX by potentiating the DNA-binding ability and stability of the RUNX family ( Fig. 1 ).
Runt (Runt domain)-related transcription factor 1 was previously found to be essential mainly for definitive hematopoiesis, based on the RUNX1-knockout mouse phenotype. 1 However, no consumption of influenced in the conditional knockout mouse, although slight change was noted in platelets, suggesting that RUNX1 is not essential for hematopoiesis in adults. 8 It has been regarded as a tumor suppressor because mutation and chromosomal translocation of RUNX1 are observed in leukemia at a high rate, but this classical viewpoint has recently changed, based on our finding that WT RUNX1 is highly important for the developmental mechanisms of inv(16)(p13q22)/t (16;16)(p13;q22) leukemia (Inv16 leukemia) and mixed lineage leukemia (MLL). [9] [10] [11] These studies described the carcinogenic properties of RUNX1 in the developmental mechanism of leukemia, but the neoplastic molecular basis of RUNX1, including that of other RUNX family members, for proliferation and maintenance of leukemia is unknown.
Transcription factor p53 (TP53) is a tumor suppressor; its deficiency promotes cancerization and progression. 12 Research into the role of TP53 in human cancer has been most intense. Cancers with defective p53 are characterized by dedifferentiation, genetic instability, and metastatic potential, and they show an enhanced malignant phenotype. 13 The frequency of p53 mutation is <10% in de novo AML, but it increases depending on the cancer type. 14, 15 The relationship between p53 and the RUNX family is often discussed based on radiosensitivity experiments using an overexpression system, but functional cross-talk between RUNX1 and p53 in carcinogenicity, proliferation, and maintenance has not been elucidated at the physiological level.
Pyrrole-imidazole (PI) polyamides (PI-polyamides) enter the minor groove of the DNA double-helix structure and recognize a specific nucleotide sequence. 16, 17 Using an advanced technique to modify PI-polyamides with a nitrogen mustard alkylating agent, chlorambucil (Chb), developed by our collaborator, Professor Hiroshi Sugiyama, at the Department of Chemistry, Kyoto University Graduate School of Science (Kyoto, Japan), 18 we newly developed Chb-M' and Chb-50, which recognize and bind to the core consensus sequences 
This image is not covered by the terms of the Creative Commons license of this publication. For permission to reuse, please contact the rights holder
specific inhibition of RUNX1 results in stabilization of the p53 protein. 19 However, in the process of establishing a leukemia cell line with p53 mutation, the dominant-negative effect of mutant p53 protein inhibited the function of WT p53 and reduced RUNX1 inhibitioninduced cell suppression, revealing that the RUNX1 inhibition-induced inhibitory effects on leukemia cells are dependent on stabilization and activation of WT p53 protein. 19 It was suggested that high expression of RUNX1 in leukemia induces high expression of p53-degrading BCL11A and TRIM24, destabilizing p53 protein in leukemia cells. This indicates a previously unknown role of RUNX1 in leukemia. 
| Development and proposal of a RUNX family cluster regulation method using PI-polyamides
Pyrrole-imidazole polyamide is a superior medium-sized compound with selective binding ability to the specific nucleotide sequence in the DNA double-helix structure. We designed original molecules, PI-polyamide Chb-M' and Chb-50s, which specifically bind to the RUNX-binding consensus sequences, and evaluated the gene expression pattern of the comprehensively regulated RUNX family. The RUNX family pathway was negatively controlled and strong cell suppression effects were observed at the nanomolar concentration (nmol/L) level in leukemia cell lines. 19 In addition, the survival rate of a xenograft treatment model using immunodeficient mice was improved and no toxicity was noted in several preliminary toxicity tests. As all RUNX family members share the RUNX-binding consensus sequences 5′-TGTGGT-3′ or 5′-TGCGGT-3′, CROX was possible.
This was not possible with the RUNX1 inhibitor alone, and the compensatory mechanism of the RUNX family was successfully overcome (Fig. 3) . 19 
| Core-binding factor β as a pan-cancer marker
To establish the RUNX family cluster regulation method, we analyzed the protein and mRNA expression levels of RUNX1, RUNX2, RUNX3, and CBFβ in leukemia and different cancer cell lines. Compared with that in normal-type cells, the CBFβ expression level in tumor cells was significantly higher in both leukemia and different cancers. 19 In addition, the total protein level of the RUNX family (RUNX1 + RUNX2 + RUNX3) was positively correlated with the CBFβ protein level. Moreover, the outcome was significantly poorer in the high CBFβ expression group for all cancer types. These findings suggested that the total RUNX family expression level is correlated with CBFβ expression, and the RUNX family cluster is a common antitumor target among cancers. main causes of disease development. 25 We extracted the most important RUNX1 inhibition domain in Inv16 leukemia by establishing five types of knockout mice in which the core RUNX1 inhibition domain present in the long tail of the fusion protein was deleted. 9, 26 In D43 mice with the HABD deletion, the RUNX1-transferring effect was inhibited and RUNX1 remained in the nucleus, which moderately improved the dominant RUNX1 inhibition. However, unexpectedly, D43 chimeric mice developed Inv16 leukemia at approximately 1 week after birth, even though no additional gene abnormality was present, suggesting that dominant RUNX1 inhibition is not essential for Inv16 leukemia and RUNX1 could be targeted by treatment. were enhanced, and cell proliferation was inhibited in the marked knockdown cell lines, but the cell cycle was promoted and apoptosis induction was reduced in the moderate knockdown cell lines. 27 We newly extracted GSTA2 (intracellular ROS scavenger and cell cycle promotion factor), belonging to the GST family, as a causative gene.
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It was clarified that under the condition of moderate knockdown of RUNX1 protein, GSTA2 markedly increased and its ROS scavenger action was promoted, decreasing ROS and intracellular free radicals (H 2 O 2 ); this condition promoted the cell cycle. 27 In addition, the RUNX-binding consensus sequence is present in the GSTA2 promotor region and GSTA2 was found to be directly transcriptionally regulated by the RUNX family through efficient binding by RUNX1, RUNX2, and RUNX3. Moderate inhibition of RUNX1 most markedly increased the total RUNX family level through "genetic compensation of RUNX family transcription factors" and maximized the GSTA2 protein level, thereby reducing cell cycle promotion and induction of apoptosis. Indeed, in a mouse treatment model using a GST inhibitor, ethacrynic acid, the survival time was markedly extended (Fig. 4) . 27 
| DISCUSSION AN D CONCLUSION
Dominant inhibition of the tumor suppressor RUNX1 was previously considered to be the cause of the disease-developing proliferation maintenance mechanism, mainly in CBF leukemia. However, our study clarified that WT RUNX1 is needed for survival and proliferation of leukemia cells, suggesting that a treatment strategy targeting RUNX1 is more effective. As the RUNX family has a mechanism to compensate for loss among the family members, moderate inhibition of RUNX1 increases the total RUNX family protein level (genetic compensation of RUNX family transcription factors), and the RUNX family transcriptionally regulates the p53 inhibitor. Therefore, several groups have tried to regulate RUNX1 alone, but suppression of leukemia cells was incomplete. To overcome this, we propose comprehensive RUNX family cluster regulation (CROX) as a leukemia treatment strategy because it is difficult to individually inhibit RUNX family proteins. As PI-polyamide Chb-M' and Chb-50, currently in development, target the common consensus sequences of the RUNX family, individual inhibition of the members is not necessary.
Although the comprehensive RUNX family cluster regulation has yet to be applied, we suggest the RUNX gene switch method using PI-polyamides as a new technique that could contribute to the next generation of leukemia treatment strategies.
